Clinical trial

Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes

NCT05160272

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention AP-325 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo matching AP-325 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-01-07

PhasePHASE2

Conditions

Type2 Diabetesunresolved

Interventions

AP-325DRUG

Placebo matching AP-325DRUG

Sponsors & collaborators

The Deutsche Diabetes Forschungsgesellschaft e.V.lead sponsor

Algiax Pharmaceuticals GmbHcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05160272 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.